Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 357

1.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators.

Kidney Int. 2019 Mar 9. pii: S0085-2538(19)30041-9. doi: 10.1016/j.kint.2018.11.044. [Epub ahead of print]

PMID:
30898339
2.

OCRL Deficiency Impairs Endolysosomal Function in a Humanized Mouse Model for Lowe Syndrome and Dent Disease.

Festa BP, Berquez M, Gassama A, Amrein I, Ismail HM, Samardzija M, Staiano L, Luciani A, Grimm C, Nussbaum RL, De Matteis MA, Dorchies OM, Scapozza L, Wolfer DP, Devuyst O.

Hum Mol Genet. 2018 Dec 26. doi: 10.1093/hmg/ddy449. [Epub ahead of print]

PMID:
30590522
3.

The patient with metabolic alkalosis.

Gillion V, Jadoul M, Devuyst O, Pochet JM.

Acta Clin Belg. 2018 Oct 27:1-7. doi: 10.1080/17843286.2018.1539373. [Epub ahead of print]

PMID:
30369299
4.

The excretion of uromodulin is modulated by the calcium-sensing receptor.

Tokonami N, Olinger E, Debaix H, Houillier P, Devuyst O.

Kidney Int. 2018 Nov;94(5):882-886. doi: 10.1016/j.kint.2018.07.022.

5.

Combined Structural and Functional Imaging of the Kidney Reveals Major Axial Differences in Proximal Tubule Endocytosis.

Schuh CD, Polesel M, Platonova E, Haenni D, Gassama A, Tokonami N, Ghazi S, Bugarski M, Devuyst O, Ziegler U, Hall AM.

J Am Soc Nephrol. 2018 Nov;29(11):2696-2712. doi: 10.1681/ASN.2018050522. Epub 2018 Oct 9.

PMID:
30301861
6.

Uromodulin and Nephron Mass.

Pivin E, Ponte B, de Seigneux S, Ackermann D, Guessous I, Ehret G, Pechère-Bertschi A, Olinger E, Mohaupt M, Vogt B, Martin PY, Burnier M, Bochud M, Devuyst O, Pruijm M.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1556-1557. doi: 10.2215/CJN.03600318. Epub 2018 Jul 27. No abstract available.

PMID:
30054352
7.

Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC.

Tokonami N, Takata T, Beyeler J, Ehrbar I, Yoshifuji A, Christensen EI, Loffing J, Devuyst O, Olinger EG.

Kidney Int. 2018 Oct;94(4):701-715. doi: 10.1016/j.kint.2018.04.021. Epub 2018 Jul 12.

8.

Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane.

Morelle J, Sow A, Fustin CA, Fillée C, Garcia-Lopez E, Lindholm B, Goffin E, Vandemaele F, Rippe B, Öberg CM, Devuyst O.

J Am Soc Nephrol. 2018 Jul;29(7):1875-1886. doi: 10.1681/ASN.2017080828. Epub 2018 May 29.

PMID:
29844208
9.

Defective autophagy degradation and abnormal tight junction-associated signaling drive epithelial dysfunction in cystinosis.

Luciani A, Festa BP, Chen Z, Devuyst O.

Autophagy. 2018;14(7):1157-1159. doi: 10.1080/15548627.2018.1446625. Epub 2018 May 28.

PMID:
29806776
10.

Prevalence of Hypertension in Children with Early-Stage ADPKD.

Massella L, Mekahli D, Paripović D, Prikhodina L, Godefroid N, Niemirska A, Ağbaş A, Kalicka K, Jankauskiene A, Mizerska-Wasiak M, Afonso AC, Salomon R, Deschênes G, Ariceta G, Özçakar ZB, Teixeira A, Duzova A, Harambat J, Seeman T, Hrčková G, Lungu AC, Papizh S, Peco-Antic A, De Rechter S, Giordano U, Kirchner M, Lutz T, Schaefer F, Devuyst O, Wühl E, Emma F.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):874-883. doi: 10.2215/CJN.11401017. Epub 2018 Apr 19.

PMID:
29674338
11.

NRF2 regulates the glutamine transporter Slc38a3 (SNAT3) in kidney in response to metabolic acidosis.

Lister A, Bourgeois S, Imenez Silva PH, Rubio-Aliaga I, Marbet P, Walsh J, Shelton LM, Keller B, Verrey F, Devuyst O, Giesbertz P, Daniel H, Goldring CE, Copple IM, Wagner CA, Odermatt A.

Sci Rep. 2018 Apr 4;8(1):5629. doi: 10.1038/s41598-018-24000-2.

12.

Claudins: a tale of interactions in the thick ascending limb.

Olinger E, Houillier P, Devuyst O.

Kidney Int. 2018 Mar;93(3):535-537. doi: 10.1016/j.kint.2017.09.032.

PMID:
29475543
13.

Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies.

Ashton EJ, Legrand A, Benoit V, Roncelin I, Venisse A, Zennaro MC, Jeunemaitre X, Iancu D, Van't Hoff WG, Walsh SB, Godefroid N, Rotthier A, Del Favero J, Devuyst O, Schaefer F, Jenkins LA, Kleta R, Dahan K, Vargas-Poussou R, Bockenhauer D.

Kidney Int. 2018 Apr;93(4):961-967. doi: 10.1016/j.kint.2017.10.016. Epub 2018 Feb 15.

PMID:
29398133
14.

Peritoneal dialysis beyond kidney failure?

Pratsinis A, Devuyst O, Leroux JC.

J Control Release. 2018 Jul 28;282:3-12. doi: 10.1016/j.jconrel.2018.01.017. Epub 2018 Jan 31.

PMID:
29360477
15.

Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney.

Festa BP, Chen Z, Berquez M, Debaix H, Tokonami N, Prange JA, Hoek GV, Alessio C, Raimondi A, Nevo N, Giles RH, Devuyst O, Luciani A.

Nat Commun. 2018 Jan 11;9(1):161. doi: 10.1038/s41467-017-02536-7.

16.

Genetics of kidney diseases in 2017: Unveiling the genetic architecture of kidney disease.

Devuyst O.

Nat Rev Nephrol. 2018 Feb;14(2):80-82. doi: 10.1038/nrneph.2017.177. Epub 2018 Jan 8. No abstract available.

PMID:
29307891
17.

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.

Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD.

Kidney Int Rep. 2017 Jul 21;2(6):1132-1140. doi: 10.1016/j.ekir.2017.07.004. eCollection 2017 Nov.

18.

Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study.

Canivell S, Mohaupt M, Ackermann D, Pruijm M, Guessous I, Ehret G, Escher G, Pechère-Bertschi A, Vogt B, Devuyst O, Burnier M, Martin PY, Ponte B, Bochud M.

J Endocrinol Invest. 2018 Jul;41(7):799-808. doi: 10.1007/s40618-017-0807-7. Epub 2017 Dec 12.

PMID:
29235050
19.

Mechanisms of acid-base regulation in peritoneal dialysis.

Sow A, Morelle J, Hautem N, Bettoni C, Wagner CA, Devuyst O.

Nephrol Dial Transplant. 2018 May 1;33(5):864-873. doi: 10.1093/ndt/gfx307.

PMID:
29186492
20.

The UMOD Locus: Insights into the Pathogenesis and Prognosis of Kidney Disease.

Devuyst O, Pattaro C.

J Am Soc Nephrol. 2018 Mar;29(3):713-726. doi: 10.1681/ASN.2017070716. Epub 2017 Nov 27.

21.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

22.

Genome-Wide Meta-Analysis Unravels Interactions between Magnesium Homeostasis and Metabolic Phenotypes.

Corre T, Arjona FJ, Hayward C, Youhanna S, de Baaij JHF, Belge H, Nägele N, Debaix H, Blanchard MG, Traglia M, Harris SE, Ulivi S, Rueedi R, Lamparter D, Macé A, Sala C, Lenarduzzi S, Ponte B, Pruijm M, Ackermann D, Ehret G, Baptista D, Polasek O, Rudan I, Hurd TW, Hastie ND, Vitart V, Waeber G, Kutalik Z, Bergmann S, Vargas-Poussou R, Konrad M, Gasparini P, Deary IJ, Starr JM, Toniolo D, Vollenweider P, Hoenderop JGJ, Bindels RJM, Bochud M, Devuyst O.

J Am Soc Nephrol. 2018 Jan;29(1):335-348. doi: 10.1681/ASN.2017030267. Epub 2017 Nov 1.

23.

Suppression of microRNA Activity in Kidney Collecting Ducts Induces Partial Loss of Epithelial Phenotype and Renal Fibrosis.

Hajarnis S, Yheskel M, Williams D, Brefort T, Glaudemans B, Debaix H, Baum M, Devuyst O, Patel V.

J Am Soc Nephrol. 2018 Feb;29(2):518-531. doi: 10.1681/ASN.2017030334. Epub 2017 Oct 11.

24.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.

25.

Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Aymé S, Bockenhauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfinger JR, Klein JB, Knoers NVAM, Perrone RD, Roberts J, Schaefer F, Torres VE, Cheung M, Wheeler DC, Winkelmayer WC; Conference Participants.

Kidney Int. 2017 Oct;92(4):796-808. doi: 10.1016/j.kint.2017.06.018. Erratum in: Kidney Int. 2017 Dec;92(6):1558.

26.

The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.

Clark WF, Devuyst O, Roussel R.

J Intern Med. 2017 Oct;282(4):310-321. doi: 10.1111/joim.12654. Epub 2017 Sep 14. Review.

PMID:
28905441
27.

A population-based approach to assess the heritability and distribution of renal handling of electrolytes.

Moulin F, Ponte B, Pruijm M, Ackermann D, Bouatou Y, Guessous I, Ehret G, Bonny O, Pechère-Bertschi A, Staessen JA, Paccaud F, Martin PY, Burnier M, Vogt B, Devuyst O, Bochud M.

Kidney Int. 2017 Dec;92(6):1536-1543. doi: 10.1016/j.kint.2017.06.020. Epub 2017 Sep 6.

PMID:
28888328
28.

Uromodulin: from physiology to rare and complex kidney disorders.

Devuyst O, Olinger E, Rampoldi L.

Nat Rev Nephrol. 2017 Sep;13(9):525-544. doi: 10.1038/nrneph.2017.101. Epub 2017 Aug 7. Review.

PMID:
28781372
29.

Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX syndrome.

Hadj-Rabia S, Brideau G, Al-Sarraj Y, Maroun RC, Figueres ML, Leclerc-Mercier S, Olinger E, Baron S, Chaussain C, Nochy D, Taha RZ, Knebelmann B, Joshi V, Curmi PA, Kambouris M, Vargas-Poussou R, Bodemer C, Devuyst O, Houillier P, El-Shanti H.

Genet Med. 2018 Feb;20(2):190-201. doi: 10.1038/gim.2017.71. Epub 2017 Aug 3.

PMID:
28771254
30.

Seasonality of sodium and potassium consumption in Switzerland. Data from three cross-sectional, population-based studies.

Marti-Soler H, Pommier C, Bochud M, Guessous I, Ponte B, Pruijm M, Ackermann D, Forni Ogna V, Paccaud F, Burnier M, Pechère-Bertschi A; Swiss Survey on Salt Group, Devuyst O, Marques-Vidal P.

Nutr Metab Cardiovasc Dis. 2017 Sep;27(9):792-798. doi: 10.1016/j.numecd.2017.06.012. Epub 2017 Jul 4.

PMID:
28756972
31.

The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.

De Matteis MA, Staiano L, Emma F, Devuyst O.

Nat Rev Nephrol. 2017 Aug;13(8):455-470. doi: 10.1038/nrneph.2017.83. Epub 2017 Jul 3. Review.

PMID:
28669993
32.

A novel homozygous UMOD mutation reveals gene dosage effects on uromodulin processing and urinary excretion.

Edwards N, Olinger E, Adam J, Kelly M, Schiano G, Ramsbottom SA, Sandford R, Devuyst O, Sayer JA.

Nephrol Dial Transplant. 2017 Dec 1;32(12):1994-1999. doi: 10.1093/ndt/gfx066.

33.

Validation of Surrogates of Urine Osmolality in Population Studies.

Youhanna S, Bankir L, Jungers P, Porteous D, Polasek O, Bochud M, Hayward C, Devuyst O.

Am J Nephrol. 2017;46(1):26-36. doi: 10.1159/000475769. Epub 2017 Jun 7.

34.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079. No abstract available.

PMID:
28444221
35.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043.

36.

NFAT5 and SLC4A10 Loci Associate with Plasma Osmolality.

Böger CA, Gorski M, McMahon GM, Xu H, Chang YC, van der Most PJ, Navis G, Nolte IM, de Borst MH, Zhang W, Lehne B, Loh M, Tan ST, Boerwinkle E, Grams ME, Sekula P, Li M, Wilmot B, Moon JG, Scheet P, Cucca F, Xiao X, Lyytikäinen LP, Delgado G, Grammer TB, Kleber ME, Sedaghat S, Rivadeneira F, Corre T, Kutalik Z, Bergmann S, Nielson CM, Srikanth P, Teumer A, Müller-Nurasyid M, Brockhaus AC, Pfeufer A, Rathmann W, Peters A, Matsumoto M, de Andrade M, Atkinson EJ, Robinson-Cohen C, de Boer IH, Hwang SJ, Heid IM, Gögele M, Concas MP, Tanaka T, Bandinelli S, Nalls MA, Singleton A, Tajuddin SM, Adeyemo A, Zhou J, Doumatey A, McWeeney S, Murabito J, Franceschini N, Flessner M, Shlipak M, Wilson JG, Chen G, Rotimi CN, Zonderman AB, Evans MK, Ferrucci L, Devuyst O, Pirastu M, Shuldiner A, Hicks AA, Pramstaller PP, Kestenbaum B, Kardia SLR, Turner ST, Study LC, Briske TE, Gieger C, Strauch K, Meisinger C, Meitinger T, Völker U, Nauck M, Völzke H, Vollenweider P, Bochud M, Waeber G, Kähönen M, Lehtimäki T, März W, Dehghan A, Franco OH, Uitterlinden AG, Hofman A, Taylor HA, Chambers JC, Kooner JS, Fox CS, Hitzemann R, Orwoll ES, Pattaro C, Schlessinger D, Köttgen A, Snieder H, Parsa A, Cohen DM.

J Am Soc Nephrol. 2017 Aug;28(8):2311-2321. doi: 10.1681/ASN.2016080892. Epub 2017 Mar 30.

37.

A mouse model for inherited renal fibrosis associated with endoplasmic reticulum stress.

Piret SE, Olinger E, Reed AAC, Nesbit MA, Hough TA, Bentley L, Devuyst O, Cox RD, Thakker RV.

Dis Model Mech. 2017 Jun 1;10(6):773-786. doi: 10.1242/dmm.029488. Epub 2017 Mar 21.

38.

The Hypertension Pandemic: An Evolutionary Perspective.

Rossier BC, Bochud M, Devuyst O.

Physiology (Bethesda). 2017 Mar;32(2):112-125. doi: 10.1152/physiol.00026.2016. Review.

39.

The NLRP3 Inflammasome Has a Critical Role in Peritoneal Dialysis-Related Peritonitis.

Hautem N, Morelle J, Sow A, Corbet C, Feron O, Goffin E, Huaux F, Devuyst O.

J Am Soc Nephrol. 2017 Jul;28(7):2038-2052. doi: 10.1681/ASN.2016070729. Epub 2017 Feb 13.

40.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

Am J Nephrol. 2017;45(3):257-266. doi: 10.1159/000456087. Epub 2017 Feb 7.

41.

Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease.

Gabriel SS, Belge H, Gassama A, Debaix H, Luciani A, Fehr T, Devuyst O.

Kidney Int. 2017 Apr;91(4):842-855. doi: 10.1016/j.kint.2016.11.016. Epub 2017 Jan 28.

PMID:
28143656
42.

Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O, Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R.

Kidney Int. 2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046.

43.

SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function.

Li M, Li Y, Weeks O, Mijatovic V, Teumer A, Huffman JE, Tromp G, Fuchsberger C, Gorski M, Lyytikäinen LP, Nutile T, Sedaghat S, Sorice R, Tin A, Yang Q, Ahluwalia TS, Arking DE, Bihlmeyer NA, Böger CA, Carroll RJ, Chasman DI, Cornelis MC, Dehghan A, Faul JD, Feitosa MF, Gambaro G, Gasparini P, Giulianini F, Heid I, Huang J, Imboden M, Jackson AU, Jeff J, Jhun MA, Katz R, Kifley A, Kilpeläinen TO, Kumar A, Laakso M, Li-Gao R, Lohman K, Lu Y, Mägi R, Malerba G, Mihailov E, Mohlke KL, Mook-Kanamori DO, Robino A, Ruderfer D, Salvi E, Schick UM, Schulz CA, Smith AV, Smith JA, Traglia M, Yerges-Armstrong LM, Zhao W, Goodarzi MO, Kraja AT, Liu C, Wessel J; CHARGE Glycemic-T2D Working Group,; CHARGE Blood Pressure Working Group,, Boerwinkle E, Borecki IB, Bork-Jensen J, Bottinger EP, Braga D, Brandslund I, Brody JA, Campbell A, Carey DJ, Christensen C, Coresh J, Crook E, Curhan GC, Cusi D, de Boer IH, de Vries AP, Denny JC, Devuyst O, Dreisbach AW, Endlich K, Esko T, Franco OH, Fulop T, Gerhard GS, Glümer C, Gottesman O, Grarup N, Gudnason V, Hansen T, Harris TB, Hayward C, Hocking L, Hofman A, Hu FB, Husemoen LL, Jackson RD, Jørgensen T, Jørgensen ME, Kähönen M, Kardia SL, König W, Kooperberg C, Kriebel J, Launer LJ, Lauritzen T, Lehtimäki T, Levy D, Linksted P, Linneberg A, Liu Y, Loos RJ, Lupo A, Meisinger C, Melander O, Metspalu A, Mitchell P, Nauck M, Nürnberg P, Orho-Melander M, Parsa A, Pedersen O, Peters A, Peters U, Polasek O, Porteous D, Probst-Hensch NM, Psaty BM, Qi L, Raitakari OT, Reiner AP, Rettig R, Ridker PM, Rivadeneira F, Rossouw JE, Schmidt F, Siscovick D, Soranzo N, Strauch K, Toniolo D, Turner ST, Uitterlinden AG, Ulivi S, Velayutham D, Völker U, Völzke H, Waldenberger M, Wang JJ, Weir DR, Witte D, Kuivaniemi H, Fox CS, Franceschini N, Goessling W, Köttgen A, Chu AY.

J Am Soc Nephrol. 2017 Mar;28(3):981-994. doi: 10.1681/ASN.2016020131. Epub 2016 Dec 5.

44.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.

J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5.

45.

Common variants in CLDN14 are associated with differential excretion of magnesium over calcium in urine.

Corre T, Olinger E, Harris SE, Traglia M, Ulivi S, Lenarduzzi S, Belge H, Youhanna S, Tokonami N, Bonny O, Houillier P, Polasek O, Deary IJ, Starr JM, Toniolo D, Gasparini P, Vollenweider P, Hayward C, Bochud M, Devuyst O.

Pflugers Arch. 2017 Jan;469(1):91-103. doi: 10.1007/s00424-016-1913-7. Epub 2016 Dec 3. Review.

PMID:
27915449
46.

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators.

Am J Kidney Dis. 2017 Feb;69(2):210-219. doi: 10.1053/j.ajkd.2016.08.028. Epub 2016 Nov 14.

47.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators.

Nephrol Dial Transplant. 2016 Nov;31(11):1887-1894. Epub 2015 Dec 17.

48.

The Current State of Peritoneal Dialysis.

Mehrotra R, Devuyst O, Davies SJ, Johnson DW.

J Am Soc Nephrol. 2016 Nov;27(11):3238-3252. Epub 2016 Jun 23. Review.

49.

TRPV4 participates in pressure-induced inhibition of renin secretion by juxtaglomerular cells.

Seghers F, Yerna X, Zanou N, Devuyst O, Vennekens R, Nilius B, Gailly P.

J Physiol. 2016 Dec 15;594(24):7327-7340. doi: 10.1113/JP273595. Epub 2016 Dec 2.

50.

Editors' Digest - Basic Science A Wearable Sweat Analyzer for Continuous Electrolyte Monitoring.

Youhanna S, Devuyst O.

Perit Dial Int. 2016 Sep 10;36(5):470-1. doi: 10.3747/pdi.2016.00098. No abstract available.

Supplemental Content

Loading ...
Support Center